


Accepted Manuscript

The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression

Olivia I. Okereke, Charles F. Reynolds, David Mischoulon, Grace Chang, Nancy R. Cook, Trisha Copeland, Georgina Friedenber, Julie E. Buring, JoAnn E. Manson



PII: S1551-7144(17)30635-3
DOI: doi:[10.1016/j.cct.2018.02.017](https://doi.org/10.1016/j.cct.2018.02.017)
Reference: CONCLI 1716
To appear in: *Contemporary Clinical Trials*
Received date: 28 September 2017
Revised date: 19 February 2018
Accepted date: 27 February 2018

Please cite this article as: Olivia I. Okereke, Charles F. Reynolds, David Mischoulon, Grace Chang, Nancy R. Cook, Trisha Copeland, Georgina Friedenber, Julie E. Buring, JoAnn E. Manson , The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Concli(2018), doi:[10.1016/j.cct.2018.02.017](https://doi.org/10.1016/j.cct.2018.02.017)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**The VITamin D and OmegA-3 Trial-Depression Endpoint Prevention (VITAL-DEP):
rationale and design of a large-scale ancillary study evaluating vitamin D and marine
omega-3 fatty acid supplements for prevention of late-life depression**

Olivia I. Okereke, MD, SM^{1,2,4,6}, Charles F. Reynolds III, MD⁸, David Mischoulon, MD, PhD⁴,
Grace Chang, MD^{1,5}, Nancy R. Cook, ScD^{3,6}, Trisha Copeland, MS, RD³, Georgina Friedenber,
MPH³, Julie E. Buring, ScD^{3,6}, JoAnn E. Manson, MD, DrPH^{3,6}

From the Department of Psychiatry¹, and the Channing Division of Network Medicine² and
Division of Preventive Medicine³, Department of Medicine, Brigham and Women's Hospital and
Harvard Medical School, Boston, MA; Department of Psychiatry⁴, Massachusetts General
Hospital and Harvard Medical School, Boston, MA, USA; Department of Psychiatry⁵, VA
Boston Healthcare System, Brockton, MA, USA; Department of Epidemiology⁶, Harvard T. H.
Chan School of Public Health, Boston, MA, USA; Department of Psychiatry⁸, UPMC and
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Address correspondence to Dr. Olivia I. Okereke, Massachusetts General Hospital Department of
Psychiatry, One Bowdoin Square, Boston, MA 02114. Email: ookereke@partners.org.

Running title, character count: VITAL-DEP prevention study, 26

Abstract word count: 248

Introduction word count: 499

Discussion word count: 1,270

Main text word count: 5,987

Figures and Tables: 5

Download English Version:

<https://daneshyari.com/en/article/8757539>

Download Persian Version:

<https://daneshyari.com/article/8757539>

[Daneshyari.com](https://daneshyari.com)